Journal
PHARMACOPSYCHIATRY
Volume 43, Issue 3, Pages 86-91Publisher
GEORG THIEME VERLAG KG
DOI: 10.1055/s-0029-1242817
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [30772553]
- National Great Project of New Drug Innovation [20081201, 20081202]
- Shanghai Municipal Science and Technology Commission [07DJ14005]
- Shanghai Rising-Star Program [08QA14042]
Ask authors/readers for more resources
Introduction: The objective of this study is to take into consideration the influence of baseline risk on the treatment effect and evaluate the effectiveness of standardized Ginkgo biloba extract (GbE) on cognitive symptoms of dementia with the treatment period of approximately 6 months. Methods: We systematically searched the literature to identify all randomized placebo-controlled clinical trials (English language) of GbE in the treatment of dementia. Data were extracted from selected trials and combined with standard meta-analysis methods. A bivariate meta-analysis was carried out to further estimate the effect size of GbE. Results: The random effect estimate of standard mean difference (SMD) between GbE and placebo groups of 6 selected trials was -0.89 (95% CI -1.82 to 0.04) in the assessment of cognitive function. Bivariate random effect estimate of difference of change in ADAS-cog scores was -2.65 (95% CI -4.53 to -0.76), which showed a significant difference in favor of GbE. Conclusion: Considering baseline risk in the assessment of treatment effect, GbE was found to be effective for cognitive functions in dementia with the treatment of 6 months
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available